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Abstract
Background: Despite the evidence that many stroke survivors report longer term unmet needs, the provision of longer
term care is limited. To address this, we are conducting a programme of research to develop an evidence-based and
replicable longer term care strategy. The developed complex intervention (named New Start), which includes needs
identification, exploration of social networks and components of problem solving and self-management, was designed to
improve quality of life by addressing unmet needs and increasing participation.
Methods/Design: A multicentre, cluster randomised controlled feasibility trial designed to inform the design
of a possible future definitive cluster randomised controlled trial (cRCT) and explore the potential clinical and
cost-effectiveness of New Start.
Ten stroke services across the UK will be randomised on a 1:1 basis either to implement New Start or continue with
usual care only. New Start will be delivered by trained facilitators and will be offered to all stroke survivors within the
services allocated to the intervention arm. Stroke survivors will be eligible for the trial if they are 4–6 months
post-stroke and residing in the community. Carers (if available) will also be invited to take part. Invitation to
participate will be initiated by post and outcome measures will be collected via postal questionnaires at 3, 6
and 9 months after recruitment. Outcome data relating to perceived health and disability, wellbeing and
quality of life as well as unmet needs will be collected. A ‘study within a trial’ (SWAT) is planned to
determine the most acceptable format in which to provide the postal questionnaires. Details of health and social care
service usage will also be collected to inform the economic evaluation. The feasibility of recruiting services and stroke
survivors to the trial and of collecting postal outcomes will be assessed and the potential for effectiveness will be
investigated. An embedded process evaluation (reported separately) will assess implementation fidelity and explore
and clarify causal assumptions regarding implementation.
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Discussion: This feasibility trial with embedded process evaluation will allow us to gather important and detailed data
regarding methodological and implementation issues to inform the design of a possible future definitive cRCT of this
complex intervention.
Trial Registration: ISRCTN38920246. Registered 22 June 2016.
Keywords: Stroke, Longer term, Feasibility trial, Community, Study within a trial (SWAT), Facilitated self-management,
Complex intervention, Cluster trial
Background
Stroke remains a major illness, with over 1 million
people living in the United Kingdom who have had a
stroke and over 100,000 people who suffer a stroke
each year. Almost two-thirds of stroke survivors leave
hospital with a disability [1]. The early stages of the
stroke care pathway are becoming more prescribed
(treatment in acute and rehabilitation stroke units),
but despite policy recommendations, strategies for
longer term care are not developed and longer term
outcomes remain poor for many stroke survivors and
their carers [2–4]. Many stroke survivors report un-
met needs 1–5 years after stroke [5]. To address the
limited provision of longer term stroke care, we have
developed a new intervention designed to form part
of a replicable ‘care strategy’ aimed at improving
stroke survivors’ quality of life by addressing unmet
needs and enhancing participation.
The developed intervention, called New Start, involves an
assessment of stroke survivors’ needs and a review of their
social networks at approximately 6 months post-stroke
(purposely coinciding with national guidelines for a
6-month review of health and social care needs [6]). An
open process then seeks to enable stroke survivors to ad-
dress their identified needs and includes components of
problem solving and self-management. The intervention is
delivered by trained staff we call the New Start facilitator(s).
Herein, we describe the protocol for a feasibility trial
intended to inform the design of a possible future defini-
tive randomised controlled trial (RCT) and explore the
potential clinical and cost-effectiveness of the New Start
intervention.
Methods/design
Aims and objectives
We aim to conduct a pragmatic, multicentre, cluster
randomised controlled feasibility trial of the New
Start intervention versus usual care practice. The key
objectives of this trial relate to gathering data to in-
form the feasibility and acceptability of implementing
a future definitive cluster randomised controlled trial
(cRCT); these are listed below and described in more
detail in Additional file 1.
1. Stroke service recruitment methods and uptake
2. Stroke survivor recruitment methods and uptake
3. Intervention implementation and delivery
4. Definition of usual care
5. Assessment of outcome measures, potential for
effectiveness and data gathering to assess the
intracluster correlation coefficient (ICC)
6. Assessment of cost and cost-effectiveness
7. Safety
Figure 1 illustrates the timing of all trial processes
(Additional file 2).
Setting
Stroke service eligibility criteria
The study will be conducted in 10 United Kingdom (UK)
National Health Service (NHS) stroke services. A stroke
service is defined by fulfilling a set of criteria, namely (1)
encompasses the stroke pathway from secondary (hos-
pital) care to primary/community-based care over a de-
fined geographical area within the UK and (2) includes a
stroke unit (given that treatment in a stroke unit is the
recommended care pathway for all patients after a stroke
[6, 7]). Stroke services will be included in this feasibility
trial if they agree to try and establish a robust mechanism
to identify all stroke survivors at 4–6 months post-stroke
and have the facilities and capacity to deliver the New
Start intervention, including training (i.e. staff available to
undertake training and provide face-to-face contact with
community-based stroke survivors at least 6 months
post-stroke). Stroke services that have previously partici-
pated in research leading to the development of the inter-
vention or that are currently or intending to implement a
service comparable with the New Start intervention (e.g. a
self-management focussed approach) within the proposed
duration of the study will not be eligible.
All participating sites will be requested to complete a
site survey documenting current service provision (includ-
ing number of patients offered their service in the last 6
months) when expressing interest in the study, as well as
at pre-randomisation (baseline), pre-recruitment and dur-
ing recruitment (i.e. three monthly until the end of the
follow-up period). This survey will allow capture of usual
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care and assessment and documentation of any change in
stroke service provision (aside from the New Start inter-
vention) during the course of the trial. The baseline survey
will inform stratification factors for randomisation. Senti-
nel Stroke National Audit Programme (SSNAP) data will
be reviewed to assess usual patient throughput in each
service to enable comparison with recruitment rates dur-
ing the trial.
Stroke survivor eligibility
Stroke survivors will be eligible for inclusion in the
study if they (1) are at least 4 months and not more
than 6 months since confirmed primary diagnosis of
new stroke; (2) are residing in the community (i.e.
not in a nursing or residential care home); (3) are in-
cluded within the defined population covered by the
stroke service; (4) provide informed consent or con-
sultee declaration; and (5) return a completed base-
line questionnaire.
It is unknown whether the New Start intervention
can be delivered to stroke survivors with other (spe-
cific) co-morbidities. Therefore, no exclusion criteria
will be applied and reasons for not being offered or
provided the New Start intervention at 6 months
post-stroke (for those in a service so randomised) will
be documented and used to inform eligibility criteria
for a definitive trial.
Carer eligibility
Carer involvement is not a requirement for stroke
survivor inclusion in this trial. All carers identified
by the stroke survivor as the main informal caregiver
who provides the stroke survivor with support a
minimum of once per week and who provide in-
formed consent (i.e. implied via return of completed
baseline questionnaire) will be eligible for inclusion
in the study.
Unit of randomisation
Cluster randomisation will reduce the likelihood of
between-group treatment contamination. The New
Start intervention aims to impact on skills, knowledge
and clinical practice, and therefore the risk of contam-
ination will be high if randomisation is at the individual
stroke survivor level. All identified stroke survivors will
be offered the opportunity to receive the allocated
treatment and therefore it is not possible to use the pa-
tient as the unit of randomisation. Allocation of stroke
services (clusters) to intervention or control will be
undertaken independently by the statistician at the
Fig. 1 SPIRIT figure. *Interventions delivered at site level for duration of trial until at least 2 months after participant recruitment approach has
ended. $Further detail is provided in Table 1. % Timepoints are post-randomisation
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Clinical Trials Research Unit (CTRU). Stroke services
will be allocated on a 1:1 basis to either implement
the New Start intervention or continue with usual
care only, using minimisation with a random element.
Minimisation factors will be the number of stroke
survivors seen by community teams per annum
(above and below the median across all recruited ser-
vices) and whether recruitment and intervention are
delivered at separate Trusts (Yes/ No).
Intervention
Intervention development was based on the principles of
the Medical Research Council (MRC) framework for the
development of complex interventions [8]. Details of the
development of the intervention will be published separ-
ately. Briefly, a series of systematic literature reviews
helped us identify the key unmet needs in the target popu-
lation and interventions that had previously been evalu-
ated. A national survey captured existing service models
whereas focus group discussions and interviews with ser-
vice users and carers provided important insights into the
form and content of an acceptable intervention. The inter-
vention was then developed using a structured process
that involved exploration of this primary data to gain an
understanding of the needs of stroke survivors and carers
as well as potential outcomes of the intervention, and con-
vening a multi-disciplinary expert group to co-design the
intervention, in conjunction with the programme manage-
ment team and consumer reference advisory group. We
used a range of approaches to develop the intervention
plan, including techniques derived from problem structur-
ing, priority-setting and knowledge mobilisation. The
emerging intervention and trial methodology were refined
in a pilot study in three stroke services.
The resulting intervention, called New Start, is a
programme of facilitated self-management that aims to
improve longer term outcomes for stroke survivors. The
emphasis is on improving quality of life by addressing
unmet needs and enhancing participation, and is deliv-
ered in one-to-one meetings that are guided by princi-
ples of patient centredness, empowerment for patients
and carers, and open availability for feedback.
The intervention involves an initial assessment of
stroke survivors’ needs and a review of their social net-
works. An open process facilitated by trained staff then
seeks to enable survivors to address their identified
needs and use components of problem solving – priori-
tising needs, action planning, goal setting, and reviewing
as well as self-management. At each stage, participants
are encouraged to see those in their social network as
resources to help in this process. Intervention delivery
will be recorded by the New Start facilitators on
purposely designed activity records.
New Start facilitator and training
The intervention is delivered by trained staff we call the
New Start facilitator(s). All activities relating to delivery
of the training and intervention implementation will be
fully documented to provide a record of fidelity in terms
of study design and provider training, informed by the
Borelli framework [9].
Stroke services randomised to the intervention arm
will identify New Start facilitator(s) who will be trained
in the intervention. The number of facilitators required
in each stroke service will depend on the size of the ser-
vice and available staff. However, it is anticipated that
approximately two facilitators will be trained at each
stroke service. It is anticipated that the New Start facili-
tators will have experience in one of the following roles:
Nurse, Physiotherapist, Occupational Therapist, Health
and Wellbeing Practitioner, or other Allied Health Pro-
fessional training, and will have stroke-specific know-
ledge and/or training.
New Start training will entail attending a structured
training course involving face-to-face training supported
by additional written materials. During the training, facili-
tators will learn relevant theory about a self-management
approach and communication skills, as well as specific
details about the intervention and how to deliver it to
stroke survivors.
The New Start facilitators will be assessed for compe-
tency in the delivery of the New Start intervention,
through review of patient activity records, reflective
reports, interviews and observation, approximately
16 weeks after completing the initial training course (or
earlier if appropriate).
Delivery and monitoring of the New Start intervention
The New Start intervention will be offered to all stroke
survivors within the stroke services allocated to the
intervention arm. Compliance with the New Start inter-
vention will be monitored throughout the trial via obser-
vations and regular collection of activity records to
assess adherence, to understand whether the New Start
facilitators deliver the intervention in accordance with
training and ‘as intended’. A parallel process evaluation
(to be published separately) will enable evaluation of the
training package and implementation process.
Usual care
Stroke services randomised to the usual care control
group will continue to deliver care as determined by
local policy and practices. Our earlier survey work
demonstrated that the provision of longer term sup-
port for stroke survivors is variable across the coun-
try. A total of 203 services in England were surveyed
and, out of those who responded (n = 115), it was
found that 70% commission community stroke
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services beyond 6 months. We plan to systematically
collect data on usual care provision in all participat-
ing services.
Recruitment and consent
Screening and approaching stroke survivors for inclu-
sion in the trial will commence at all stroke services
approximately 12 weeks post-randomisation to allow
time for the New Start facilitators to be trained in
the intervention.
Identification and screening of stroke survivors
Methods to identify stroke survivors and their carers (if
available) by site staff may vary between sites, but it is
anticipated that identification will be through routine
data – this may include locally held registers or the
SSNAP data. The proposed identification mechanism
will be clarified with the local sites to ensure that the
methods are inclusive of all stroke survivors and not a
select sub-sample (e.g. only stroke survivors referred to
an early supported-discharge team) and can be under-
taken independent of the staff delivering any interven-
tion to participants (in either arm) in order to reduce
the potential for selection bias from differential recruit-
ment, a particular concern in cRCTs [10].
A consecutive sample of stroke survivors will be iden-
tified and screened for eligibility on survival status and
place of residence by site recruitment staff at participat-
ing stroke services.
The New Start facilitators in the intervention arm will
have access to a list of all consecutive post-stroke survi-
vors in their defined catchment area.
Approach and informed consent
Recruitment procedures have been designed to be as
flexible as possible in order to optimise engagement
with this study. Eligible stroke survivors will be initially
approached via a letter inviting them to take part in the
trial. Site staff will have the option to chase up any
non-responders via telephone. Stroke survivors who ex-
press interest in the study are asked to indicate a pref-
erence for completion of baseline questionnaires, either
face-to-face or by post. They can also gain further in-
formation about the study by telephone.
Those stroke survivors interested in taking part will
be provided with a baseline questionnaire pack, which
will include a consent form, by their preferred method.
In addition to consent to complete outcome assess-
ments, participants will be asked if they consent to
No
Stroke survivor/consultee sent the following by the Site Staff 
• Invitation Letters for stroke survivor and consultee
• Survivor Information Sheet 
• Reply form 
• Pre-paid postage envelope.
Stroke survivor is eligible. Questionnaire pack is provided to the 
stroke survivor/consultee as per preference 
Exclude  
Exclude  
Reply, 
request more 
information
No reply 
within 7 days 
Reply, 
not interested
Reply, 
interested, 
eligible 
Stroke survivors are screened for the following:
• 4 months and 6 months since confirmed primary 
diagnosis of new stroke. 
• Residing in the community.
• Care covered by the stroke service.
Site staff call stroke survivor/consultee
1. Provide more information 
2. Confirm Interest 
3. Determine preference for data collection 
If site staff are unable to make contact via telephone they 
will send out a reminder letter.
Yes
Not interested / 
unable to contact / 
not eligible  
Interested, eligible  
a b
Stroke survivor/consultee does not return 
questionnaire pack within 10 days:
The site staff will contact the stroke 
survivor/consultee to determine if received the 
questionnaire, if still interested, or if require a 
face to face visit (as applicable). 
If site staff are unable to make contact via 
telephone they will send out a reminder letter.
Registration
If, after the stroke survivor/consultee 
has the questionnaires and is not 
returned within a further 14 days, it 
will be assumed that the stroke 
survivor/consultee is no longer 
interested and will be excluded and 
documented on the Screening Form. 
Stroke survivor/consultee 
consents and completes 
questionnaire pack at visit 
Stroke survivor/consultee 
returns questionnaire pack  
Stroke survivor/consultee is 
left the questionnaire pack to 
return via post. 
Face to face visit 
Post
Questionnaire Pack sent to stroke 
survivor/consultee by post. 
Face to face
Site staff telephone the stroke survivor/consultee 
to arrange a visit. The visit is confirmed in writing 
including the questionnaire pack. 
Stroke survivor/consultee is provided with questionnaire pack in 
accordance with preference provided on the reply form
Stroke 
survivor/consultee 
returns 
questionnaire 
Fig. 2 a Participant identification flow diagram. b Baseline consent and questionnaire completion flow diagram
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permit access to their electronic healthcare records.
Figure 2 illustrates the participant identification and
baseline consent and questionnaire completion
processes.
Carer consent
Carer information packs, including a baseline question-
naire booklet, will be provided to the stroke survivor
with their baseline questionnaire pack with a request to
pass on to a carer if appropriate. Consent of the carer
will be implied if the baseline carer questionnaire is
returned completed.
Lack of capacity
To ensure that the trial population is representative of
the clinical stroke population and inclusive of stroke sur-
vivors with cognitive impairment (including receptive,
comprehension or language difficulties), procedures for
Consultee Declaration will be implemented in compli-
ance with the Mental Capacity Act 2005.
As it may not be clear at the time of approach whether
the stroke survivor may lack capacity to consent for them-
selves, an invitation letter for a potential consultee, the
stroke survivor’s family member, carer or friend, will be
enclosed with all invitation letters posted out. All stroke
survivor/consultee and carer information and consent
documentation can be found in Additional file 3.
Study withdrawal
Stroke survivors (or where stroke survivors lack capacity,
their consultee) and carers will be free to withdraw con-
sent and leave the study at any time without giving rea-
sons and without their care being affected. We will
clarify whether they are withdrawing from the comple-
tion of questionnaires, access to health and social care
records or both. Previously collected data will still be
used in the analyses (unless consent has been with-
drawn). Where possible, the reason for stroke survivor
and/or carer withdrawal will be collected.
Data collection
Data will be collected at the level of the service (includ-
ing staff ) as well as from individual consenting partici-
pants at baseline and at 3, 6 and 9 months post
recruitment. Personal information will be held centrally,
in accordance with consent, by the research team to
facilitate follow-up contact, but will be stored and
processed separately to all other data collected for the
purposes of the trial.
Stroke survivor
Stroke survivor screening data will be recorded by site
recruitment staff and will include, where possible, demo-
graphic characteristics (age, sex and ethnicity), hospital
admission and discharge details, Modified Rankin
Scale (mRS) score at discharge, National Institute for
Health Stroke Scale (NIHSS) score at admission and
availability of a carer. The reasons for ineligibility or for
declining participation will also be recorded.
The baseline data will also be recorded by site recruit-
ment staff and, in addition to the screening data, will in-
clude where possible: date of birth, NHS identification
number, contact details, GP details, living arrangement
details, carer details (if applicable), date of stroke, details
on the level of impairment at recruitment (e.g. speech
impairment, difficulties with communication) and pre-
ferred method(s) of contact.
Baseline and follow-up assessments
One of the aims of this trial is to assess the acceptability
of the assessment methods and tools with a view to sim-
plifying this for the planned definitive cRCT. Therefore,
we have chosen not to test the use of outcome assess-
ments that have been used successfully in previous
stroke trials.
Stroke survivor Stroke survivor baseline assessments
will be administered by the site staff either in person or
by post. Stroke survivors will be followed up by the cen-
tral trial team via postal questionnaires at 3, 6 and 9
months post recruitment. This will be supported by pos-
tal, telephone and text reminders if questionnaires are
not returned within 2 weeks. Proxy completion of ques-
tionnaires by the stroke survivors’ carer/family/friend
will be permitted. If outcome measures cannot be ob-
tained by post, then telephone interviews may be con-
ducted to collect the data to maximise return of data.
Figure 3 illustrates the follow-up process.
The questionnaires will include the following validated
outcome measures:
 World Health Organization Disability Assessment
Schedule 2.0 36-item version, WHODAS 2.0 [11–
13]: a generic measure of health and disability. It
captures activity limitations and participation re-
strictions in six domains of life (understanding and
communicating, getting around, self-care, getting
along with people, life activities and participation in
society) and a summary score.
 The Warwick-Edinburgh Mental Well-being Scale,
WEMWBS [14–17]: measures feeling and function-
ing aspects
of mental wellbeing or positive mental health.
 EQ-5D with 5 levels of severity for each of the 5
dimensions (EQ-5D-5L) [18–21]: a measure of
health status or health-related quality of life
(HRQoL) for clinical and economic evaluation. It
measures problems in five domains (mobility, self
Forster et al. Trials  (2018) 19:317 Page 6 of 14
care, usual activities, pain/discomfort, anxiety/
depression) and self-rated health.
 ICEpop CAPability measure for Adults, ICECAP-A
[22–27]: measures capability for five attributes of
wellbeing (attachment, stability, achievement, en-
joyment, autonomy) for use in economic
evaluation.
 13-item Short Form Patient Activation Measure
Survey, PAM® survey [28, 29]: assesses the extent to
which people feel engaged, with the knowledge,
skills and confidence to manage a medical
condition.
 Longer-term Unmet Needs after Stroke tool, LUNS
[30]: a 22-item monitoring tool for identifying longer
term unmet needs after stroke.
 Relevant questions adapted from the Millennium
Survey of Poverty and Social Exclusion [31] and
GP Patient Survey [32].
The questionnaires will also include a single overall life
satisfaction question and a request for information about
who completed the pack (the stroke survivor or a proxy)
and how much help was provided. In addition, health,
social care and voluntary or third sector service use will
be collected together with costs to participants using a
resource use questionnaire.
Information from stroke survivors’ health and social care
records will also be collected from NHS Digital and other
routine data sources, if relevant consent has been provided
(subject to approval from the relevant data provider).
Carer Carer baseline assessments will be administered
to the carers in a similar manner to stroke survivors.
Questionnaire packs will be provided to stroke survivors
or their consultee with instructions to pass them to a
carer if one exists. These questionnaires will be adminis-
tered by post unless the carer is able to attend a
face-to-face visit requested by the stroke survivor/con-
sultee. Carers will be followed-up by the central trial
team via postal questionnaires at 3, 6 and 9 months
after stroke survivor recruitment. This will be sup-
ported by postal, telephone and text reminders if
questionnaires are not returned within 2 weeks. If
outcome measures cannot be completed by post, tele-
phone interviews will be conducted by the central
trial team to collect the data.
The questionnaires will include the Caregiver Burden
Scale [33], which assesses the burden experienced by
caregivers of people with chronic disability, EQ-5D-5L
and ICECAP-A. Health, social care and voluntary or
third sector service use will be collected together with
costs to the carer using a resource use questionnaire.
A summary of the stroke survivor and carer assess-
ment schedule is given in Table 1.
Method of administration The questionnaires consist
of a number of outcome measures alongside a resource
use questionnaire. We would like to determine the most
acceptable format in which to provide these question-
naires in order to maximise follow up rates for the
future definitive trial. We therefore have planned a study
Questionnaire is returned
Stroke survivors/consultees and carers are 
given two weeks to complete and return the 
questionnaires
Questionnaire is not returned
After two weeks the stroke 
survivor/consultee/carer will be sent a 
further pack with a reminder letter. 
Follow-up packs
Follow-up packs are sent out by the CTRU at three, six and nine months post-
registration* directly to the stroke survivor/consultee/carer (as applicable). 
Packs consist of:
Questionnaire for stroke survivor/consultee/carer (as applicable)
Covering letter
Postage paid envelopes
Questionnaire returned
Follow-up continues until the 9 month 
questionnaire is returned.
No response
CTRU will attempt to contact the stroke 
survivor/consultee/carer via telephone and 
offer to collect data by telephone.
Fig. 3 Follow-up flow diagram. *Prior to posting the follow-up pack the CTRU will confirm the stroke survivors’ and carers’ survival status and
current address. Subject to consent and collection of phone number from the stroke survivor/consultee/carer; CTRU will send reminders to the
stroke survivor/consultee/carer via Short Message Service (SMS) text message as a prompt to complete the questionnaires
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within a trial (SWAT) [34] where we will randomise the
method of delivery of the outcome assessments. This
means that stroke survivors (and carers where available)
will receive, at random, follow-up questionnaires in one
of the following formats: one booklet (including all mea-
sures) or two (one including the outcome measures and
the other with the resource use questionnaire). Random-
isation will be undertaken independently by the CTRU
just prior to the 6 months follow-up time point. Stroke
survivors will be randomised on a 1:1 basis to receive
the questionnaires in the formats indicated above at the
six and nine month follow up time points (where applic-
able, the carer will receive the format allocated to the
stroke survivor).
Data collection on care received
Details regarding usual care at each participating site will
be captured by the site survey.
In addition, stroke service clinical staff in all partici-
pating sites will be asked to keep an activity record for
each stroke survivor they offer/provide a service to six
months after their stroke. Intervention specific activity
records will also be completed by the facilitators deliver-
ing the New Start intervention; this will enable audit of
the number of stroke survivors in receipt of the New
Start intervention, as well as assessment of the adher-
ence and fidelity of the intervention delivered.
NHS Digital data will also be used to provide informa-
tion on hospital admissions and outpatient attendance
received by each of the stroke survivors during the
course of the trial (from time of recruitment to nine
months post-recruitment).
Safety reporting
We will collect data on related and unexpected serious ad-
verse events. Expected events such as death of a stroke
Table 1 Summary and timing of stroke survivor and carer assessments
Assessment Screening Baseline Time-point (post registration)
3 months 6 months 9 months
Screening X
Eligibility X
Informed consent/Consultee declaration X
Baseline X
Registration X
Stroke Survivor Questionnaires
Demographic details X
WHODAS 2.0 X X X
WEMWBS X X X
PAM® Survey X X X
EQ-5D-5L X X X X
ICECAP-A X X X X
LUNS X X
GP patient survey (two questions) X X X
Social questions X X X
Health and social care resource use (stroke survivor and provider reported) X X X X
Adverse events X X X
Hospital admissions X X X
Carer Questionnaires
Demographic details (on each carer if applicable) X (X) (X) (X)
Caregiver Burden Scale X X X X
ICECAP-A X X X X
EQ-5D-5L X X X X
Health and social care resource use X X X X
EQ-5D-5L EQ-5D with 5 levels of severity for each of the 5 dimensions, ICECAP-A ICEpop CAPability measure for Adults, LUNS Longer-term Unmet Needs after Stroke
tool, PAM Patient Activation Measure, WEMWBS Warwick-Edinburgh Mental Well-being Scale, WHODAS World Health Organization Disability Assessment Schedule
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survivor / carer or institutionalisation will also be re-
corded and will be collected from the date of consent until
nine months post-recruitment. We are exploring the feasi-
bility of using routine data for collecting this information.
Blinding
Blinding in cluster trials is particularly problematic.
We are implementing a range of strategies to try and
maintain blinding where possible. The recruiting team
will not be informed of the outcome of the cluster
randomisation and therefore the treatment allocation
for their site. This will allow us to minimise bias in
the recruitment process.
In order to minimise any treatment bias, the New Start
facilitators will not be informed of which of their pa-
tients are participating in the trial.
Where incidents of unblinding do occur, site staff
(from recruitment and clinical teams) will be asked to
inform the study team as soon as possible providing
detailed information on the circumstances surround-
ing the incident. This will allow such incidents to be
fully documented and reported on and this informa-
tion will be used to inform the design of the future
definitive trial.
Process evaluation
A parallel process evaluation will be undertaken based
on the MRC guidance for conducting process evalua-
tions of complex interventions [8, 35] and Grant’s frame-
work for process evaluations of cluster-randomised trials
[36]. Process evaluation methods were subject to a sep-
arate ethics application and will be described in a separ-
ate paper. In brief summary here, the primary objectives
of the process evaluation are to:
1. Assess implementation fidelity.
2. Explore and clarify causal assumptions regarding
implementation.
3. Investigate the contextual factors associated with
variations in intermediate outcomes between sites
(e.g. levels of available resources, staff ).
4. Explore the views, perceptions and acceptability of the
intervention to facilitators, stroke survivors and carers.
5. Test and refine methods of data collection and
interrogation in preparation for a process evaluation
alongside a future effectiveness trial.
We also propose to explore with the recruitment team
at each site the barriers and facilitators to the recruit-
ment process.
Economic evaluation
The economic evaluation will assess the cost effective-
ness of New Start compared to usual care using both a
within trial cost effectiveness analysis and a longer term
cost effectiveness model. Both analyses will take a soci-
etal perspective including health and social care, volun-
tary and third sector providers together with costs to
stroke survivors and their informal carers.
The analyses will use the Quality-Adjusted Life Year
(QALY) outcome measure [37]. The estimation of
QALYs is based on health-related quality of life
(HRQoL) scores for health states and the EQ-5D-5L
instrument will be used for this purpose [38, 39]. The
EQ-5D-5L responses collected from stroke survivors
and their carers will generate HRQoL scores using the
UK population tariff. The potential for aggregating
stroke survivor and carer QALYs within the economic
analyses as well as alternative instruments to assess
carers’ HRQoL will be explored. In addition, stroke
survivors’ WHODAS 2.0 scores collected within the
study will be mapped to their EQ-5D-5L scores, in
order to add to the evidence base.
Data from earlier work-streams of the LoTS2Care
programme will be used to identify mediators and mod-
erators for consideration in the analyses. Data from the
feasibility cRCT will further explore whether these vari-
ables could have a potential mediating or moderating ef-
fect on the economic evaluation.
Resource use (healthcare, social care, voluntary and
third sector) together with out of pocket expenses
and productivity losses will be collected by way of
the stroke survivor and carer resource use question-
naires. The added value of NHS Digital and other
routine data sources to collect healthcare resource
use in any subsequent definitive cRCT will also be
explored.
Unit costs for health service resources will be
obtained from national sources such as the Personal
Social Services Research Unit, the British National
Formulary and the NHS Reference cost database.
Where national unit costs are not available, the fi-
nance departments of Trusts participating in the
study will be asked to provide local cost data. In line
with recommendations from the National Institute for
Health and Care Excellence, costs and outcomes will
be discounted at 3.5% per annum [37].
Sample size
We aim to recruit 200 stroke survivors (though the
actual number of stroke survivors may be higher than
this to account for uptake of the intervention and
losses to follow-up) from 10 sites over a period of ap-
proximately 6 months. We judge it is achievable to
recruit three to four stroke survivors from each site
per month.
As this is a feasibility study, formal power calculations
are not appropriate as clinical effectiveness is not being
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evaluated. The results generated from this study, including
robust estimates for non-compliance and loss to follow-up
rates in this patient group, will be used to inform the
power calculation for a possible definitive study.
Statistical analysis
Statistical analysis is the responsibility of the University of
Leeds CTRU statistician, and a final statistical analysis plan
will be written prior to any analysis being undertaken. All
analyses and data summaries will be conducted on the
intention-to-treat population, defined as all stroke survivors
recruited, regardless of non-compliance with the protocol
or withdrawal from the study. No formal interim or
sub-group analyses are planned, and final analysis will take
place when all available data have been received. The ana-
lysis will be focussed on descriptive statistics and confi-
dence interval (CI) estimation rather than on formal
hypothesis testing.
Estimation of stroke service and stroke survivor recruitment
uptake
The number of stroke services expressing an interest in
participation in the trial will be summarised. The num-
ber of services screened for selection together with rea-
sons for non-selection will be presented.
The feasibility and success of the stroke survivor recruit-
ment strategy will be evaluated by summarising the screen-
ing, eligibility, consent and approach processes, including
the numbers of stroke survivors involved during each stage
overall, by stroke service and by arm. Comparison with
available national datasets (e.g. SSNAP) will be undertaken
where applicable. Reasons for non-participation in the
study will be summarised.
Retention of stroke services and participants (stroke
survivors and carers) will be presented overall and by
treatment arm. The number and timing of withdrawals
of each of these from the trial, as well as reasons for
withdrawal, will also be presented overall and by treat-
ment arm. The number of New Start facilitators with-
drawing from their role and the timing of and reasons
for withdrawals (if available to us) will be summarised by
stroke service and overall.
Assessment of intervention implementation and delivery
The feasibility of the intervention will be evaluated by
summarising the numbers of New Start facilitators re-
cruited and assessed as competent, by summarising the
number of stroke services and New Start facilitators ad-
hering to the intervention, and by summarising the
number of stroke survivors completing the intervention
by services and overall. The number of stroke services
demonstrating adherence to the intervention delivery
will be evaluated by review of the activity records. The
embedded process evaluation will assess the intervention
delivery in more detail.
Assessment of usual care
Returned site surveys and activity records will be
reviewed and used to guide a definition of routine care
for use in a future definitive trial.
Assessment of outcome measures, potential for
effectiveness and data gathering to assess the ICC
The feasibility and success of obtaining the outcome
data will be assessed at each time point by summarising
the proportion of stroke survivors with available
self-reported outcome data by site, treatment arm and
overall. Follow-up rates and levels of missing data will
similarly demonstrate the acceptability of the outcome
measures. Levels of missing self-reported outcome data,
both at the individual item level and for entire outcome
measures, will be reported at each time point overall
and by treatment arm. Acceptability of methods for
obtaining the outcome data by post, face-to-face or
over the phone and burden of collecting all question-
naires will also be summarised at each time point, by
treatment arm and overall. Acceptability of the format
of the questionnaires (one questionnaire incorporating
all outcome measures and health resource use or two
separate questionnaires, one with the outcome mea-
sures and the other with the health resource use alone)
will also be summarised at each time point, by treat-
ment arm and overall.
Acceptability, availability of and completion rates for
routine data collection will be presented by site, treat-
ment arm and overall. Stroke survivors’ use of NHS ser-
vices and the number of deaths will be summarised from
routine data and reported by stroke service, treatment
arm and overall.
Eligibility and recruitment rates, along with the num-
ber of stroke survivors successfully followed up, will also
help inform the sample size by assessing the feasibility of
recruitment for the definitive trial.
Variation around the ICC estimate is likely to be large
and we will estimate the ICC after controlling for covari-
ates and constructing CIs to obtain a range of plausible
estimates, from which a variety of sample sizes for the
definitive trial can be calculated. As we may not be able
to obtain a very precise estimate from our data, we will
also compare our estimated ICC with those from other
published studies. We will summarise outcome mea-
sures, predictive and process variables by point esti-
mates, variability estimates and range of CIs (e.g. 95%,
67% and 51%) by randomised group at each time point.
In order to inform the sample size calculation for the
definitive trial and determine potential for effectiveness,
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we will calculate scores for each outcome and differ-
ences in outcomes by treatment arm together with
corresponding 95% CIs.
Assessment of cost and cost-effectiveness
The within trial cost effectiveness analysis will present an
incremental cost effectiveness ratio (ICER) and the net
monetary benefit (NMB). Missing data will be accounted
for in line with current recommended methods and un-
certainty using the bootstrapping method [40]. For the
longer term cost effectiveness, a decision model will be
developed and the results presented as an ICER and
NMB. A value of information analysis will be undertaken
in order to inform the design of any subsequent RCT.
Missing data will use current recommended methods and
sensitivity analysis using the Monte Carlo simulations will
account for uncertainty [41, 42].
Safety
All safety reports will be independently reported and
reviewed by the Programme Steering Committee (PSC).
Criteria for continuation to the definitive RCT
Criteria for progression to a definitive RCT are based on
recruitment, follow-up, and intervention implementation
and delivery. Suggested progression criteria are detailed
in Table 2 and are based on a traffic-light system of
green (go), amber (review) and red (stop). The criteria
are to be agreed by the independent PSC and funder.
Data monitoring
Overall trial supervision is provided by the PSC, with an in-
dependent Chair as well as patient and public involvement
representation. For a feasibility study of this nature and
duration, a separate Data Monitoring and Ethics Commit-
tee is not required; rather, the PSC will adopt a safety moni-
toring role, with the constitution of a sub-committee to
review safety issues where this becomes necessary.
Data will be monitored for quality and completeness
by the CTRU. Missing data, except for individual data
items collected via the postal questionnaires, will be
chased until they are received, confirmed as not
available, or when the trial is at analysis. Reminders will
be sent to participants if postal questionnaires are not
returned on time.
Trial organisation and administration
This feasibility trial is the final study in a 5-year
Programme Grant for Applied Research (grant
RP-PG-0611-20010) funded by the National Institute
for Health Research. The trial is sponsored by the
Bradford Teaching Hospitals NHS Foundation Trust
and is co-ordinated by the Academic Unit of Elderly
Care and Rehabilitation (Bradford Teaching Hospitals
NHS Foundation Trust and University of Leeds) and
the CTRU (Leeds Institute of Clinical Trials Research,
University of Leeds). The Trial Management Group is
comprised of the Chief Investigator, key co-applicants,
research fellows experienced in qualitative research
and key members of the project delivery team at the
CTRU.
The study is adopted by the UK Clinical Research
Network and is supported in part by its trained research
staff. The trial is registered (ISRCTN38920246). The trial
will be conducted in accordance with the principles of
Good Clinical Practice in clinical trials, as applicable
under UK regulations, the NHS Research Governance
Framework, and through adherence to CTRU standard
operating procedures. Ethical approval has been
obtained through the UK National Research Ethics
Service (16/YH/0068).
Dissemination
The results of the study will be published in peer-reviewed
publications and will be presented at relevant national and
international conferences. We will work with the patient
and public involvement representatives to develop lay re-
ports to disseminate research findings to patient groups
and the clinical staff at participating sites. Authorship will
be agreed in accordance with the LoTS2Care Programme
publication policy and in line with International Commit-
tee of Medical Journal Editors (ICMJE) recommendations.
Table 2 Criteria for continuation to the definitive RCT
Criteria Green Amber Red
Average recruitment of participants per site over 6 months ≥ 20 (range 12–30) < 20 but ≥ 10 < 10
Return of follow-up questionnaires ≥ 75% < 75% but ≥ 60% < 60%
Intervention training At least two members of staff from each
stroke service attending training days and
assessed as competent
Intervention delivery (% of recruited stroke survivors offered
at least one session of the intervention)
≥ 75% < 75% but ≥ 50% < 50%
Intervention implementation (% of stroke services deemed
competent and went on to deliver the intervention and
recruited participants)
≥ 80%
(i.e. 4 services)
60%
(i.e. 3 services)
< 60%
(i.e. 2 or less services)
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Discussion
Despite the evidence that many stroke survivors re-
port unmet needs, the evidence base for longer term
stroke care for stroke survivors and their carers is
limited. To address this, we are conducting a
programme of research to develop and evaluate an
evidence-based and replicable longer term care strat-
egy. We have developed the New Start intervention,
which aims to improve stroke survivors’ quality of
life by addressing unmet needs and increasing
participation.
This feasibility trial has been designed to inform the
design of a possible future definitive cRCT and explore
the potential clinical and cost-effectiveness of the New
Start intervention. Due to the complex nature of the
intervention and the design of the trial, we anticipate
some critical implementation challenges, as described
below.
Recruitment
Recruitment of stroke survivors to research undertaken
after the first weeks following the stroke is difficult as
there is no easily accessible method of identification for
clinical or research staff following discharge from hos-
pital. Here, we are testing an approach which we hope
may be replicable for other similar studies in the future.
Service need
Whilst there is evidence that longer term outcome
for people after stroke is poor, this may be from se-
lect patient groups. We are aiming to offer an inter-
vention to all stroke survivors (at 4–6 months after
their stroke). This will enable us, for the first time, to
gain greater insights into the expressed need for lon-
ger term follow-up services from a wide group of
stroke survivors, thus providing invaluable informa-
tion to inform service provision.
Implementation of the New Start intervention
A key aspect of this study is to implement and sustain a
novel and complex intervention across different stroke
service configurations. The embedded process evaluation
will allow us to monitor adherence to the intervention
and enable us to explore any barriers or enablers to the
implementation of New Start to optimise implementa-
tion in a future definitive trial.
Retention
The study involves follow-up of participants over a
period of 9 months. Retention of participants over
such a period of time may be an issue. We aim to
minimise the risk of substantial losses to follow-up by
performing postal, telephone and text reminders to
chase up missing questionnaires and conducting
telephone interviews in the event that outcome mea-
sures cannot be obtained by post.
This feasibility trial will enable us to identify any im-
portant methodological issues, assess stroke patients’
needs and intervention implementation, and collect use-
ful data on recruitment uptake and outcome measure
feasibility that will inform the design and development
of a possible future definitive RCT, which could change
the way in which longer term care is provided to stroke
survivors.
Trial status
The study commenced recruitment of stroke services in
December 2015, and recruitment of stroke survivors and
carers in January 2017. The study is projected to
complete recruitment by end of November 2017.
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